Abstract

The NCI-MATCH trial, the largest national study (1173 sites) for patients with relapsed/refractory solid tumors, lymphomas and myeloma, assigns targeted therapies based on individual tumor molecular alterations detected using clinical targeted next-generation sequencing and immunohistochemistry. It was hypothesized that patients with deleterious PTEN mutations without PTEN protein loss may benefit from treatment with the pan-PI3K inhibitor copanlisib.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call